Resource Summary Report

Generated by ASWG on Aug 10, 2026

Brilliant Violet 785(TM) anti-mouse CD3

RRID:AB_11218805
Type: Antibody

Proper Citation

BioLegend Cat# 100231, RRID:AB_11218805

Antibody Information

URL: http://antibodyregistry.org/AB_11218805

Proper Citation: BioLegend Cat# 100231, RRID:AB_11218805

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_11218805

Vendor: BioLegend

Catalog Number: 100231

Alternative Catalog Numbers: 100232

Record Creation Time: 20250819T213049+0000

Record Last Update: 20250819T231206+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-mouse CD3.

No alerts have been found for Brilliant Violet 785(TM) anti-mouse CD3.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 19 mentions in open access literature.

Listed below are recent publications. The full list is available at ASWG .

Zhang P, et al. (2026) Sympathetic-epithelial crosstalk governs tissue-resident memory T cell immunosurveillance in the skin. Cell, 189(5), 1323.

Li M, et al. (2026) SAICAR Drives T Regulatory Cell Differentiation and FOXP3 Maintenance to Promote Immunotherapy Resistance. Cancer research, 86(9), 2218.

Ager CR, et al. (2026) Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial. Cell reports. Medicine, 7(3), 102638.

Lucotti S, et al. (2025) Extracellular vesicles from the lung pro-thrombotic niche drive cancer-associated thrombosis and metastasis via integrin beta 2. Cell, 188(6), 1642.

Yu J, et al. (2025) FABP5 in skin macrophages mediates saturated fat-induced IL-1? signaling in psoriatic inflammation. Cell reports, 44(9), 116254.

Fatkhullina AR, et al. (2025) Medullary stromal cells define small intestinal lymph node identity in humans and mice. Cell reports, 44(10), 116441.

Lai P, et al. (2025) Mitochondrial DNA released by senescent tumor cells enhances PMN-MDSC-driven immunosuppression through the cGAS-STING pathway. Immunity, 58(4), 811.

Mooser C, et al. (2025) Diet-derived LPS determines intestinal IgA induction and repertoire characteristics independently of the microbiota. Immunity, 58(7), 1778.

Braun LM, et al. (2025) Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity. Cancer cell, 43(2), 269.

Zhang X, et al. (2025) MAIT cells protect against sterile lung injury. Cell reports, 44(2), 115275.

Adamska JZ, et al. (2023) Ablation of Adar1 in myeloid cells imprints a global antiviral state in the lung and heightens early immunity against SARS-CoV-2. Cell reports, 42(1), 112038.

Bancaro N, et al. (2023) Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer. Cancer cell, 41(3), 602.

Domenjo-Vila E, et al. (2023) XCR1+ DCs are critical for T cell-mediated immunotherapy of chronic viral infections. Cell reports, 42(2), 112123.

van der Sluis TC, et al. (2023) OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum. Cell reports. Medicine, 4(3), 100939.

Jakob MO, et al. (2023) ILC3s restrict the dissemination of intestinal bacteria to safeguard liver regeneration after surgery. Cell reports, 42(3), 112269.

Riding AM, et al. (2022) Group 3 innate lymphocytes make a distinct contribution to type 17 immunity in bladder defence. iScience, 25(7), 104660.

Frost JN, et al. (2021) Hepcidin-Mediated Hypoferremia Disrupts Immune Responses to Vaccination and Infection. Med (New York, N.Y.), 2(2), 164.

Chen YG, et al. (2019) N6-Methyladenosine Modification Controls Circular RNA Immunity. Molecular cell, 76(1), 96.

Hiebert P, et al. (2018) Nrf2-Mediated Fibroblast Reprogramming Drives Cellular Senescence by Targeting the Matrisome. Developmental cell, 46(2), 145.